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Comparison of effects of amphotericin B deoxycholate
infused over 4 or 24 hours: randomised controlled trial
Urs Eriksson, Burkhard Seifert, Andreas Schaffner
Abstract
Objective To test the hypothesis that amphotericin B
deoxycholate is less toxic when given by continuous
infusion than by conventional rapid infusion.
Design Randomised, controlled, non›blinded, single
centre study.
Setting University hospital providing tertiary clinical
care.
Patients 80 mostly neutropenic patients with
refractory fever and suspected or proved invasive
fungal infections.
Intervention Patients were randomised to receive
0.97 mg/kg amphotericin B by continuous infusion
over 24 hours or 0.95 mg/kg by rapid infusion over
four hours.
Main outcome measures Patients were evaluated for
side effects related to infusion, nephrotoxicity, and
mortality up to three months after treatment. Analysis
was on an intention to treat basis.
Results Patients in the continuous infusion group had
fewer side effects and significantly reduced
nephrotoxicity than those in the rapid infusion group.
Overall mortality was higher during treatment and
after three months’ follow up in the rapid infusion
than in the continuous infusion group.
Conclusion Continuous infusions of amphotericin B
reduce nephrotoxicity and side effects related to
infusion without increasing mortality.
Introduction
Amphotericin B deoxycholate has remained the main›
stay of treatment for life threatening fungal infections
in immunocompromised patients because of its broad
fungicidal activity and cheapness. Treatment with
amphotericin B, however, is associated with acute reac›
tions related to infusion and dose dependent nephro›
toxicity. It is recommended that amphotericin B is
infused slowly over two to six hours, based on the
assumption that the severity and frequency of toxic
reactions increase during more rapid infusions.1–4
Incorporation of amphotericin B into liposomal
formulations reduces its toxicity, but the reasons for
this are unclear.5–11 As liposomes do not specifically tar›
get fungal cells it would seem that the reduction in tox›
icity, at least in part, depends on a slower delivery of
amphotericin B to tissues. The question as to whether
a slower delivery of amphotericin B from lipid formu›
lations might be reproduced by a slow infusion rate
therefore arises. The hypothesis that a continuous
infusion of amphotericin B results in reduced toxicity
has not been addressed yet in a prospective study. We
therefore conducted a randomised, controlled, and
open trial to compare the toxicity of amphotericin B
given as a continuous infusion with a conventional
rapid regimen over four hours.
Patients and methods
Inclusion and exclusion criteria and treatment
All consecutive patients at our tertiary referral centre
for adult internal medicine (Zurich University Hospi›
tal), including those at the medical intensive care unit,
were considered eligible for entry to the study, provid›
ing their doctors had decided to start treatment with
amphotericin B. Exclusion criteria were a baseline
serum creatinine concentration in excess of 300
ìmol/l or systemic treatment with amphotericin B
within the past seven days.
Patients received either a continuous (24 hours) or
a rapid (four hours) infusion of amphotericin B. The
drug was given in 500 ml of 5% glucose without any
additives through a separate intravenous line. To take
into account clinical practice patterns, doctors were
free to adjust the drug dose during the study if neces›
sary.
Drugs to prevent chills or fever were prohibited on
day 1 of entry to the study.12 To reduce nephrotoxicity
from amphotericin B all patients received infusions of
saline as standard care.13–15 The protocol gave no other
restrictions on the use of any concomitant treatment.
Outcome measures
Chills, rigors, and vomiting were monitored prospec›
tively. Each patient completed a standardised question›
naire daily until the end of the study and was
interviewed regularly. We also evaluated nursing charts
for any other adverse reaction. Temperature was
measured at least three times daily. Fever was defined
as a core temperature of at least 39.3°C (core tempera›
ture readings are 1°C above the peripheral tempera›
ture readings). The concentrations of C reactive
protein were determined every 24 hours during the
first three days and at least every other day thereafter.
Serum creatinine concentrations were measured
daily during treatment. To obtain a variable for
nephrotoxicity independent of age and body mass, we
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used a model of calculated creatinine clearance based
on lean body mass.16 17 This model predicts accurately
the change in creatinine clearance from serum
creatinine values. It works equally for patients with
either stable or unstable renal function. Creatinine
clearance per lean body mass may be calculated
according to the formula ClLBM = E/S + [600×(S1›S2)/
(T×S)], where S is the mean of two serum creatinine
values S1 and S2, T is the time interval between S1 and
S2, and E corresponds to an age dependent urinary
creatinine excretion rate in mg/min/50 kg lean body
mass.17
Electrolytes, pH, and venous bicarbonate concen›
trations were measured every other day. Hypokalaemia
was defined as a serum potassium concentration less
than 2.5 mmol/l and hypomagnesaemia as a serum
magnesium concentration less than 0.5 mmol/l,
regardless of any enteral or parenteral substitution.
Efficacy was monitored for overall mortality, mortality
due to invasive fungal infections, and breakthrough
fungaemia during treatment.
Statistics and study ethics
Analysis was on an intention to treat basis. The design
of our trial was based on a prior power calculation for
the calculated serum creatinine clearance at the end of
treatment. The possible difference between the study
arms was estimated from a retrospective analysis of
patients receiving amphotericin B at our centre. We
planned to randomise 40 patients to each arm so as to
achieve a power of 90% for the detection of an effect
size of [difference]/[standard deviation] = 0.8 when
applying a two sided t test at the 5% level. For the cal›
culated creatinine clearance, this corresponds to a dif›
ference of at least 20 ml/min between the treatments,
assuming a standard deviation of 25 ml/min within
each group.
We present continuous data as the median (range),
which were evaluated using the Mann›Whitney U test.
The effect of treatment was reported as the difference
of medians between study groups. We calculated the
differences of medians with the Hodge›Lehmann esti›
mator and the confidence intervals of median
differences with the exact distribution of the Mann›
Whitney test statistic.18 We present dichotomous data
as the number of patients, analysed with Fisher’s exact
test. We report the effect of amphotericin B treatment
for dichotomous data as relative risk. Confidence inter›
vals for relative risks were obtained as described previ›
ously.19 We considered differences for which P < 0.05
significant.
Study ethics—Our study was approved by the institu›
tional ethics committee of Zurich University Hospital.
We obtained written consent from all patients at enrol›
ment.
Assignment
The initial dosage for amphotericin B was chosen
before randomisation by the doctors in charge, who
were not members of the study team. Eligible patients
were then randomised in blocks of 10 by sealed
envelope. Treatment started immediately after ran›
domisation.
Results
Patient flow and follow up
Figure 1 shows the flow of patients through the trial.
Patients were followed up three months after
completion of treatment or when treatment was
discontinued for any reason.
Analysis
Patients—Overall, 86 consecutive patients received
amphotericin B during the study period. Most of them
were severely neutropenic, with haematological neo›
plasias. Of these patients, only three had not been
reported to the study team. One patient was not eligi›
ble because of amphotericin B treatment within the
past seven days, and two did not give their consent. We
Patients considered for treatment with
amphotericin B deoxycholate (n=86)
40 allocated to
4 hours' infusion
Patients not enrolled (n=6):
  Not reported (n=3)
  Refused (n=2)
  Had treatment with amphotericin B
    within past 7 days (n=1)
Discontinuations (n=2):
 Refractory leukaemia (n=1)
 Severe toxicity from
   treatment (n=1)
 Died (n=7)
Patients randomised (n=80)
40 allocated to
24 hours' infusion
Completed
treatment (n=31)
Completed
treatment (n=39)
Assessed after 3
months' follow up
(n=26)
Assessed after 3
months' follow up
(n=35)
Discontinuation because
of refractory leukaemia
(n=1)
Died (n=4)Died (n=5)
Randomisation
Fig 1 Trial profile
Table 1 Dosages of amphotericin B deoxycholate and characteristics of patients
receiving rapid (four hours) and continuous (24 hours) infusions of the drug. Values
are numbers (percentages) of patients unless stated otherwise
Infusion rate
Rapid (n=40) Continuous (n=40)
Median age (range) 46 (20›75) 47 (17›74)
Median (range) No of days of treatment 12 (3›51) 16 (3›89)
Median (range) maximum daily dose (mg/kg) 0.95 (0.4›1.2) 0.96 (0.5›1.5)
Median (range) cumulative dose (mg/kg) 10.8 (2.1›42.7) 14.3 (1.8›89.0)
Male 22 27
Diagnosis:
Acute myeloid leukaemia 29 (73) 25 (63)
Acute lymphatic leukaemia 4 (10) 5 (13)
Lymphoma 4 (10) 5 (13)
Solid tumour 2 (5) 2 (5)
HIV 0 2 (5)
Others 1 (3) 1 (3)
Neutropenia (<500/ìl) 36 (90) 37 (93)
Concurrent treatment:
Aminoglycosides 18 (45) 22 (55)
Vancomycin 10 (25) 11 (28)
Diuretics 18 (45) 16 (40)
Granulocyte colony stimulating factor 13 (33) 18 (45)
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enrolled 80 patients. The study population also
included patients with moderately impaired renal
function (baseline serum creatinine concentration less
than 300 ìmol/l). The groups did not differ
significantly with regard to treatment with aminoglyco›
sides, vancomycin, diuretics, and granulocyte colony
stimulating factor. No patient received cyclosporin
(table 1). At enrolment the two groups did not differ
significantly regarding number of patients with refrac›
tory fever and probable and proved fungal infections
(table 2).
Dosage and dose reductions—Overall duration of
treatment and cumulative and daily doses did not differ
significantly between the groups. There was a
non›significant trend towards longer duration of treat›
ment and higher cumulative doses in the continuous
infusion group. We observed significantly more dose
reductions or infusion interruptions due to side effects
in the rapid infusion group (table 3).
Side effects—The major side effects related to
infusion were chills, fever, and vomiting. They occurred
mainly during the first three days of treatment. We also
observed flushing reactions, rashes, and headaches.
Patients receiving continuous infusions had fewer side
effects. We found significantly more patients with fever
in the rapid infusion group during the first 24 hours
after treatment had started (fig 2). For those who had
fever at the beginning of treatment there was also a
significant difference in the mean time to deferves›
cence (table 3). The concentrations of C reactive
protein did not differ between the two groups at entry
to the study, but there was a significant increase in the
rapid infusion group 24 and 48 hours after the start of
treatment. Concentrations gradually decreased from
baseline levels in the continuous infusion group (fig 3).
Reflecting the reduced frequency of side effects in the
continuous infusion group, these patients were less
likely to receive drugs directed against febrile reactions
or chills after the first treatment day (table 3).
Nephrotoxicity—The serum creatinine concentration
or calculated creatinine clearance did not differ
between the two groups at baseline. Comparing the
ratio of peak serum creatinine to baseline creatinine
concentrations during and at the end of treatment, we
found a significantly higher ratio in the rapid infusion
group (table 4). The increase in serum creatinine con›
centration was reversible in all but two patients, both
assigned to the rapid infusion group, within three
months after treatment had been completed. Compari›
son of the calculated creatinine clearance ratios
between both infusion groups illustrates a significantly
less impaired creatinine clearance for patients with
Table 2 Indications for treatment with amphotericin B deoxycholate, by rapid (four
hours) or continuous (24 hours) infusion. Values are numbers (percentages) of
patients
Infusion rate
Rapid (n=40) Continuous (n=40)
Refractory fever 18 (45) 12 (30)
Possible fungal infection 12 (30) 8 (20)
Probable fungal infection 10 (25) 17 (43)
Proved fungal infection 0 3* (8)
* Cryptococcosis (two patients), pulmonary aspergillosis (one).
Definitions
Refractory fever
Persistent fever for more than 72 hours despite
antibiotics in patients who are neutropenic (less than
500 neutrophils/ìl)
Possible fungal infections
Persistent fever, neutropenia, chest symptoms, or the
presence of pulmonary infiltrations on chest
radiographs
Probable fungal infections
Persistent fever or increased concentration of C
reactive protein, neutropenia, and infiltrates
characteristic of fungal pneumonia on a computed
tomogram
Proved fungal infections
Typical infiltrates on a computed tomogram and
detection of moulds in bronchoalveolar lavage or
bronchial secretions by culture and microscopy during
neutropenia, or presence of pathogenic fungi in
usually sterile sites
Table 3 Infusion related side effects and drugs to suppress febrile reactions in patients
receiving rapid (four hours) or continuous (24 hours) infusions of amphotericin B
deoxycholate. Values are numbers (percentages) of patients unless stated otherwise
Infusion rate
P value
Relative risk
(95% CI)
Rapid
(n=40)
Continuous
(n=40)
Reactions on day 1:
Fever* 21 (53) 10 (25) 0.021 2.1 (1.1 to 3.9)
Chills or rigors 21 (53) 5 (13) 0.0003 4.2 (1.8 to 10)
Vomiting 14 (35) 4 (10) 0.009 3.5 (1.3 to 9.7)
Headache 4 (10) 0
Others 1 (3) 0
Overall reactions:
Chills or rigors 25 (63) 8 (20) 0.0001 3.1 (1.6 to 6.1)
Vomiting 24 (60) 11 (28) 0.004 2.2 (1.2 to 3.8)
Headache 11 (28) 4 (10)
Others 8 (20) 2 (5)
Drugs after day 1:
Meperidine 20 (50) 6 (15) 0.002 3.3 (1.5 to 7.4)
Steroids 18 (45) 3 (8) 0.0001 6 (1.9 to 19)
Acetaminophen 30 (75) 19 (48) 0.021 1.6 (1.1 to 2.3)
Dose reductions or infusion interruption 11 (28) 3 (8) 0.022 3.7 (1.1 to 12)
Median (range) defervescence† (days) 2 (1›10) 1 (1›4) 0.016 −1 (−2 to 0)‡
*>39.3°C core temperature (corresponding to an axillary temperature of 38.3°C).
†Fever within 24 hours before treatment was documented for 26 patients in the rapid infusion group and 22
patients in the continuous infusion group.
‡Median difference.
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Fig 2 Percentage of patients with fever during first days of treatment
with amphotericin B
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continuous infusions during and at the end of
treatment (table 4).
The proportion of patients who had hypokalaemia
or hypomagnesaemia did not differ significantly
between the two groups. Hypokalaemia was observed
in 10 patients in the rapid infusion group and four
patients in the continuous infusion group. Hypomag›
nesaemia occurred in 19 patients in the rapid infusion
group and 17 patients in the continuous infusion
group (table 4).
Efficacy
All seven deaths during treatment occurred in the
rapid infusion group. Necropsy was carried out in six
of these seven cases and severe pneumonia was found.
Invasive fungi were proved in three cases; in one case
Pneumocystis carinii was detected. In two patients no
infection was found. Breakthrough fungaemia did not
occur in any patient of either group (table 5).
Treatment was discontinued in two patients
assigned to rapid infusion: one because of refractory
leukaemia and the other because of severe nephrotox›
icity from treatment. Treatment was discontinued in
one patient in the continuous infusion group because
of refractory leukaemia. None of the patients with
refractory disease showed invasive mycosis at necropsy.
After 3 months’ follow up the two groups still
differed with regard to death (table 5). All patients
recovered from neutropenia, with the exception of
those who died or where treatment had been
discontinued.
Discussion
Continuous infusions of amphotericin B are signifi›
cantly better tolerated than rapid infusions. Similar
advantages of continuous infusions could be sought
for other toxic drugs—for example, antineoplastic
agents. Continuous applications are, however, not fea›
sible if high peak values are necessary for efficacy (that
is, with aminoglycosides). The rapid infusion of
amphotericin B over fewer hours has been adopted
empirically in clinical practice. Despite a retrospective
analysis suggesting fewer side effects from continuous
infusions, no controlled trials have compared rapid
and continuous infusions of amphotericin B .2
Our study was not blinded for practical reasons.
Nevertheless, differences in toxicity between groups
were evident regarding C reactive protein and
creatinine concentrations, which were assessed at
predetermined times and were not biased by the non›
blinded study design. The reduction of side effects by
continuous infusion of amphotericin B seems compa›
rable to recent reports of liposomal amphotericin B
(table 6),8 despite higher daily and cumulative doses
being given in our study. Amphotericin B triggers a
proinflammatory response by activating different
cytokines.20 21 Continuous infusions may be better
tolerated because of delayed induction or release of
such mediators, as reflected by differences in
concentrations of C reactive protein and fever. We also
observed a noticeable reduction of nephrotoxicity in
the continuous infusion group. The mechanisms
involved in amphotericin B nephrotoxicity are not yet
fully understood.15 They can be broken down into pre›
tubular and tubular effects. Pretubular effects, which
include mainly a decrease in renal blood flow and
glomerular filtration rate, are clearly reduced in
patients having continuous infusions, as suggested by
only a small decrease in calculated creatinine
clearance. No noticeable difference was found in tubu›
lar effects between the two groups. Hypokalaemia was
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Fig 3 C reactive protein (CRP) concentrations during treatment with
amphotericin B compared with baseline levels, expressed as median
of ÄCRP (ÄCRP=CRP-CRPbaseline) in mg/l
Table 4 Nephrotoxicity in patients receiving rapid (four hours) or continuous (24 hours) infusion of amphotericin B deoxycholate.
Values are median (range) unless stated otherwise
Infusion rate
P value Median difference (95% CI)Rapid (n=40) Continuous (n=40)
Serum creatinine concentration (ìmol/l):
Baseline serum creatinine 78 (51›128) 78 (54›165)
Maximal creatinine:baseline 1.62 (0.94›3.42) 1.25 (0.91›2.53) 0.005 −0.26 (−0.49 to−0.08)
Creatinine at end of study:baseline 1.55 (0.79›3.42) 1.17 (0.46›2.26) 0.001 −0.32 (−0.53 to −0.13)
Calculated creatinine clearance*:
Minimal clearance:baseline 0.62 (0.29›1.05) 0.80 (0.39›1.10) 0.013 0.12 (0.03 to 0.22)
Clearance at end of study:baseline 0.65 (0.29›1.26) 0.86 (0.44›1.91) 0.001 0.19 (0.09 to 0.29)
Electrolyte abnormalities:
No (%) with hypokalaemia (<2.5 mmol/l) 10 (25) 4 (10)
No (%) with hypernatraemia (>155 mmol/l) 3 (8) 2 (5)
No (%) with hypomagnesaemia (<0.5 mmol/l) 19 (48) 17 (43)
Venous bicarbonate concentration†
Minimal bicarbonate:baseline 0.77 (0.44›1.00) 0.84 (0.59›1.37) 0.015 0.09 (0.02 to 0.17)
*Creatinine clearance per 50 kg lean body mass calculated from serum creatinine concentrations.
†Data missing for eight (rapid infusion) and five (continuous infusion) patients.
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non›significantly decreased and tubular acidosis
significantly decreased in the continuous infusion
group. These observations are comparable to those in
patients treated with liposomal amphotericin B: Walsh
et al8 found no differences in the frequency of
hypomagnesaemia between patients treated with lipo›
somal amphotericin B and those receiving amphoter›
icin B. In addition, they found only slight, although
significant, differences in the frequency of hypokalae›
mia. Our study comprised only 80 patients.
Nevertheless, hypokalaemia had been observed in 10
patients allocated to the rapid infusion arm compared
with four patients in the continuous infusion group.
Therefore, as with liposomal amphotericin B, a
continuous infusion of amphotericin B primarily
reduces pretubular toxicity.
Indications for amphotericin B in our study were
proved fungal infections, probable fungal infections,
possible fungal infections, and refractory fever during
neutropenia. Given the high mortality of invasive
mycoses after a delay in treatment, amphotericin B is
often prescribed empirically. A definitive baseline diag›
nosis of invasive mycosis would require invasive
diagnostic procedures that are seldom justified in neu›
tropenic and thrombocytopenic patients. It is therefore
scarcely ever possible to identify the true prevalence of
invasive mycoses, although clinical and radiological
criteria (computed tomography) allow some risk strati›
fication. For patients surviving proved mycoses during
aplasia it is also difficult to assess efficacy of treatment.
For instance, progressive changes in computed
tomgrams of these patients may represent ongoing
infection as well as host response after resolution of
neutropenia.22 In addition, recovery from neutropenia
in itself results in healing of invasive mycoses. As cri›
teria for efficacy we therefore chose mortality, mortality
due to invasive fungal infections, and breakthrough
fungaemia. Although our study population was small
for assessment of efficacy, the outcome was encourag›
ing for continuous infusion. We found a higher overall
mortality during amphotericin B in the rapid infusion
group. Mortality also remained significantly higher
after three months’ follow up. Despite a higher number
of proved or probable fungal infections in the continu›
ous infusion group, three patients died with proved
fungal infections at necropsy in the rapid infusion
group whereas none died in the continuous infusion
group. Accordingly, the death rate in the rapid infusion
group was strongly influenced by the occurrence of
invasive mycoses. Consequently, our data support the
notion that a continuous infusion of amphotericin B
may be at least as effective as daily infusions over four
hours. We therefore recommend continuous infusions
of amphotericin B , where practical, as an effective and
well tolerated alternative to the usual rapid infusions.
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